AGMB

AgomAb Therapeutics NV

• TipRanks·03/26 11:31

  Agomab receives U.S. patent for AGMB-447

• Reuters·03/26 11:02

  AGOMAB RECEIVES U.S. PATENT FOR AGMB-447, ITS INHALED LUNG-RESTRICTED SMALL MOLECULE INHIBITOR OF ALK5 IN DEVELOPMENT FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

• Reuters·03/26 11:01

  Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041

• Reuters·03/18 20:03

  Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement

• Reuters·03/18 20:03

  Agomab Therapeutics NV CFO Kemula Pierre Thadee Victor files Form 3 initial beneficial ownership statement

• Reuters·03/18 20:03

  Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement

• Reuters·03/18 20:02

  Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement

• Reuters·03/18 20:02

  Agomab Therapeutics NV director Colin Michael Bond files Form 3 initial beneficial ownership statement

• Reuters·03/18 20:02

  Agomab Therapeutics NV files Form 3 initial beneficial ownership statement for Chief Medical Officer Philippe Constantin Wiesel

• Reuters·03/18 20:02

  Agomab Therapeutics NV files Form 3 as Chief Business Officer Paul Henryk van der Horst reports beneficial ownership

• Reuters·03/18 20:02

  Agomab Therapeutics NV files Form 3 beneficial ownership statement for Chief Development Officer Andrea Saez Borderias

• Reuters·03/18 20:02

  Agomab Therapeutics NV files Form 3 beneficial ownership statement for General Counsel Ellen Lefever

• TipRanks·03/16 13:16

  Morgan Stanley Sticks to Its Buy Rating for AgomAb Therapeutics NV ADR (AGMB)

• TipRanks·03/10 10:36

  Morgan Stanley Sticks to Their Buy Rating for AgomAb Therapeutics NV ADR (AGMB)

• TipRanks·03/05 21:27

  AgomAb Therapeutics Updates Articles and Expands Authorized Capital Structure